Nanomerics’ technology addresses bioavailability challenges for a broad range of therapeutics, including low molecular weight hydrophobic drugs, peptides, and nucleic acid based therapeutics (plasmid, siRNA, miRNA). Specific administration routes for which the technology has demonstrated clear advantages include the oral route, transport across the blood-brain-barrier, delivery to solid tumours, as well as to the eye.
 
Nanomerics' proprietary technology is based on world leading know-how and scientific leadership in polymeric nanotechnology. Specifically, it allows fabrication of nano-scaled polymer aggregates to package or specifically interact with drugs or biological molecules and thus overcome delivery problems.
Biocompatible polymers may be tailored to form containers that package and help to solubilise the drug in aqueous media (e.g. gut fluid or blood) and thus dramatically increase the amount of drug available at the disease site (typically by a factor of ten).
 
A key advantage of the MET platform lies in the highly dynamic way drugs are encapsulated. This at once allows highly efficient drug loading as well as rapid release at the target barrier.

Biocompatible polymer based nanomedicines are also able to deliver drugs across the blood brain barrier and to date Nanomerics' technology has been used to deliver neuropeptides via the intravenous and oral routes.
Nanomerics' nanomedicines promote the absorption of poorly soluble drugs by increasing intraluminal dissolution rates and promoting transport across the gastrointestinal epithelium.
Specific product candidates are available for lucrative co-development opportunities.